A Phase 1 interventional study of Citrate-Free Mirikizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector.
Screening is required within 35 days prior to enrollment. For each participant, the total duration for of the clinical trial will be about 15 weeks, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type of participant and disease characteristics
Overtly healthy males and females as determined by medical evaluation including:
Note: participants may have chronic, stable medical conditions that, in the investigator's opinion, will not place the participant at increased risk by participating in the study, and will not interfere with interpretation of the data.
Have clinical laboratory test results:
Weight
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Medical conditions
Have a diagnosis or history of malignant disease within 5 years prior to baseline.
Prior/concomitant therapy
Have received any (that is, live attenuated) within less than 4 weeks or inactivated vaccine within less than 2 weeks before randomization.
Prior/concurrent clinical study experience
Have previously completed or withdrawn from this study or any other study investigating mirikizumab, and have previously received mirikizumab.
Diagnostic assessments
Have had any of the following types of infection within 3 months prior to screening or develops any of these infections before the randomization:
Show evidence of active or latent tuberculosis (TB).
Other exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg mirikizumab test formulation, 1 × 2-mL SC injections of 100 mg/mL citrate-free mirikizumab administered into arm/thigh/abdomen on day 1.
Drug: Citrate-Free Mirikizumab
Participants received 200 milligrams (mg) mirikizumab reference formulation, 2 × 1-milliliter (mL) subcutaneous (SC) injections of 100 mg/mL citrate-free mirikizumab administered into arm/thigh/abdomen on day 1.
Drug: Citrate-Free Mirikizumab
Administered SC
Also known as: LY3074828
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab
Cmax of Mirikizumab is reported.
Time frame: Day 1: Predose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 hours post-dose.
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Mirikizumab
AUC \[0-∞\] of Mirikizumab is reported.
Time frame: Day 1: Predose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 hours post-dose.
PK: Area Under the Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration (AUC [0-tlast]) of Mirikizumab
AUC \[0 to tlast\] of Mirikizumab is reported.
Time frame: Day 1: Predose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 hours post-dose.
| Milestone | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| Started | 249 | 249 |
| All participants who were exposed to study intervention (safety population) | 240 | 244 |
| Completed | 237 | 241 |
| Not completed | 12 | 8 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Randomized but did not receive any dose | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Physician decision | 5 | 2 |
| Withdrew: Adverse event | 1 | 1 |
Cmax of Mirikizumab is reported.
| microgram per milliliter (ug/mL) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab | 12.9 ± 40 | 13.5 ± 39 |
AUC \[0-∞\] of Mirikizumab is reported.
| microgram*day per milliliter (ug*day/mL) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Mirikizumab | 225 ± 41 | 228 ± 41 |
AUC \[0 to tlast\] of Mirikizumab is reported.
| microgram*day per milliliter (ug*day/mL) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration (AUC [0-tlast]) of Mirikizumab | 220 ± 40 | 223 ± 41 |
Collected over Baseline up to Day 74. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Mirikizumab (Reference) | 0/240 (0%) | 0/240 (0%) | 55/240 (22.9%) |
| 200 mg Mirikizumab (Test) | 0/244 (0%) | 0/244 (0%) | 48/244 (19.7%) |
| Event | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| HeadacheNervous system disorders | 9/240 | 12/244 |
| Injection site reactionGeneral disorders | 4/240 | 5/244 |
| Upper respiratory tract infectionInfections and infestations | 4/240 | 1/244 |
| Back painMusculoskeletal and connective tissue disorders | 4/240 | 0/244 |
| NauseaGastrointestinal disorders | 3/240 | 2/244 |
| PharyngitisInfections and infestations | 3/240 | 2/244 |
| HyperkalaemiaMetabolism and nutrition disorders | 3/240 | 2/244 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 3/240 | 0/244 |
| DiarrhoeaGastrointestinal disorders | 2/240 | 2/244 |
| VomitingGastrointestinal disorders | 2/240 | 0/244 |
All participants who were exposed to study intervention (Safety Population).
| Age, Continuous(years) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| Mean | 42.7 ± 11.6 | 42.4 ± 12.5 | 42.5 ± 12.1 |
| Sex: Female, Male(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| Female | 112 | 135 | 247 |
| Male | 128 | 109 | 237 |
| Ethnicity (NIH/OMB)(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| Hispanic or Latino | 111 | 108 | 219 |
| Not Hispanic or Latino | 129 | 136 | 265 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 8 | 10 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 52 | 56 | 108 |
| White | 177 | 174 | 351 |
| More than one race | 3 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| United States | 240 | 244 | 484 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in Dec 2024, 6 months.
Results were first posted in Dec 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab